220 related articles for article (PubMed ID: 23772563)
1. Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.
Weber IT; Waltman MJ; Mustyakimov M; Blakeley MP; Keen DA; Ghosh AK; Langan P; Kovalevsky AY
J Med Chem; 2013 Jul; 56(13):5631-5. PubMed ID: 23772563
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
[TBL] [Abstract][Full Text] [Related]
3. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
4. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
Kovalevsky AY; Ghosh AK; Weber IT
J Med Chem; 2008 Oct; 51(20):6599-603. PubMed ID: 18808097
[TBL] [Abstract][Full Text] [Related]
5. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Yu Y; Wang J; Shao Q; Shi J; Zhu W
Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
[TBL] [Abstract][Full Text] [Related]
7. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
8. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography.
Adachi M; Ohhara T; Kurihara K; Tamada T; Honjo E; Okazaki N; Arai S; Shoyama Y; Kimura K; Matsumura H; Sugiyama S; Adachi H; Takano K; Mori Y; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Kuroki R
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4641-6. PubMed ID: 19273847
[TBL] [Abstract][Full Text] [Related]
9. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
10. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
11. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
[TBL] [Abstract][Full Text] [Related]
12. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
[TBL] [Abstract][Full Text] [Related]
13. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor.
Hill R
Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407
[No Abstract] [Full Text] [Related]
14. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
15. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
Altman MD; Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Chellappan S; Kairys V; Fernandes MX; Gilson MK; Schiffer CA; Rana TM; Tidor B
J Am Chem Soc; 2008 May; 130(19):6099-113. PubMed ID: 18412349
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
Ghosh AK; Chapsal BD; Baldridge A; Steffey MP; Walters DE; Koh Y; Amano M; Mitsuya H
J Med Chem; 2011 Jan; 54(2):622-34. PubMed ID: 21194227
[TBL] [Abstract][Full Text] [Related]
18. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
[TBL] [Abstract][Full Text] [Related]
19. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
[No Abstract] [Full Text] [Related]
20. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
